BIMINI Biotech has developed a portfolio of proprietary small-molecule WASP modulators that have demonstrated promising anti-cancer activity in leukemia and lymphoma models as well as autoimmune diseases. To support the expansion of our preclinical pipeline, we are looking for a (biomedical) scientist with strong experience in cell biology and assay development. As a (senior) scientist,…
Lees meer
Leiden, 18 March 2026 – BIMINI Biotech is pleased to announce that it has been awarded funding through the Health~Holland International Kickstarter Call for Public-Private Partnerships 2025 for a collaborative project focused on advancing first-in-class therapeutics for acute myeloid leukemia (AML). The international consortium consists of BIMINI Biotech BV (Netherlands, project lead), Institute of Oncology…
Lees meer
Leiden, 6 January 2026 – BIMINI Biotech is pleased to announce the appointment of Dr. Helmuth van Es as an Independent Supervisory Board Member. Dr. van Es is a highly experienced biotech entrepreneur and life sciences executive, with more than 30 years of experience in drug discovery and development, company development, and strategic leadership. He…
Lees meer
BIMINI Biotech is happy to have Prof. Nathaniel Martin join the team as an advisor on chemistry, supporting the lead optimization. Prof. Martin is Professor of Biological Chemistry Institute of Biology Leiden (IBL) Leiden. He obtained his PhD degree from the University of Alberta in 2004. He subsequently performed postdoctoral studies at the University of…
Lees meer
Compound BM-011 (also known as EG-011) has been selected as molecule of the month November 2022 by Drug Hunter. Drug Hunter™ is an essential resource for the community of R&D innovators turning molecules into medicines. Drug Hunter distills the science behind emerging drugs and technologies into an easy-to-read and simple-to-search reference. Drug Hunter identified the…
Lees meer
Leiden, 19 January 2023 – BIMINI Biotech, an innovative therapeutics startup that develops new cancer drugs, has signed an exclusive license agreement with the Institute of Oncology Research (IOR) to acquire and further develop a novel first-in-class Wiskott Aldrich Syndrome protein (WASp) activator. The company aims to leverage WASp modulation to target hematological cancers. The…
Lees meer
BIMINI Biotech has been nominated from no fewer than an astounding 57 contenders, by the Association of Universities in the Netherlands (Vereniging van Universiteiten (VSNU), the Netherlands Academy of Technology and Innovation (AcTI) and Techleap as one of the 20 academic startups to compete in the finals of the second edition of the Academic Startup…
Lees meer
BIMINI Biotech moved to the PLNT centre for innovation and entrepreneurship in Leiden, thereby joining the largest life sciences cluster in the Netherlands. From this new location, we are in the perfect position to progress our pre-clinical activities on our lead compounds for cancer towards the clinic. We are happy to welcome you in our…
Lees meer
BIMINI Biotech is the proud winner of the LSW Venture Challenge. Over the course of three months, we have been working hard on the business case of our breakthrough innovation – a novel cure for triple negative breast cancer. Now, we aim to accelerate the development of our lead compound to bring it to the…
Lees meer
